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Pol283-8-specific, HLA-B*51:01-restricted, cytotoxic T cells (CTLs) play a critical role in the long-term control of HIV-1 infec-
tion. However, these CTLs select for the reverse transcriptase (RT) I135X escape mutation, which may be accumulating in circu-
lating HIV-1 sequences. We investigated the selection of the I135Xmutation by CTLs specific for the same epitope but restricted
by HLA-B*52:01. We found that Pol283-8-specific, HLA-B*52:01-restricted CTLs were elicited predominantly in chronically
HIV-1-infected individuals. These CTLs had a strong ability to suppress the replication of wild-type HIV-1, though this ability
was weaker than that of HLA-B*51:01-restricted CTLs. The crystal structure of the HLA-B*52:01-Pol283-8 peptide complex pro-
vided clear evidence that HLA-B*52:01 presents the peptide similarly to HLA-B*51:01, ensuring the cross-presentation of this
epitope by both alleles. Population level analyses revealed a strong association of HLA-B*51:01 with the I135Tmutant and a rela-
tively weaker association of HLA-B*52:01 with several I135Xmutants in both Japanese and predominantly Caucasian cohorts.
An in vitro viral suppression assay revealed that the HLA-B*52:01-restricted CTLs failed to suppress the replication of the I135X
mutant viruses, indicating the selection of these mutants by the CTLs. These results suggest that the different pattern of I135X
mutant selection may have resulted from the difference between these two CTLs in the ability to suppress HIV-1 replication.
HIV-1-specific cytotoxic T cells (CTLs) play an important rolein the control of HIV-1 replication (1–8); however, they also
select immune escape mutations (9, 10). Population level adapta-
tion of HIV to human leukocyte antigen (HLA) has been demon-
strated (11–15), suggesting that HIV-1 can successfully adapt to
immune responses previously effective against it.
It is well known that particular mutations can be selected by
CTLs specific for a single HIV-1 epitope. On the other hand, stud-
ies on HLA-associated HIV-1 polymorphisms have revealed ex-
amples of particularmutations associatedwithmultipleHLA class
I alleles (16–21), suggesting that the samemutation can be selected
by CTLs carrying different specificities in some cases. However,
the selection of the same mutation by CTLs specific for different
HIV-1 epitopes has rarely been reported. The change from Ala to
Pro at residue 146 ofGag (A146P) is a well-analyzed case. A146P is
an escape selected by not only HLA-B*57-restricted, ISW9-spe-
cific CTLs (22) but also by HLA-B*15:10-restricted and HLA-
B*48:01-restricted CTLs (15, 23, 24), although the latter CTLs
selected it by different mechanisms. The replacement of Thr with
Asn at residue 242 (T242N) of Gag is another case. This mutant is
selected by HLA-B*58:01-restricted and HLA-B*57-restricted
CTLs specific for the TW10 epitope in HIV-1 clade B- and C-in-
fected individuals (25–27).
The presence of Pol283-8(TAFTIPSI: TI8)-specific, HLA-
B*51:01-restricted CTLs is associated with low viral loads in HIV-
1-infected Japanese hemophiliacs, supporting an important role
in the long-term control of HIV-1 infection (28). We previously
showed that the frequency of a mutation at position 135 (I135X)
of reverse transcriptase (RT) is strongly correlated with the prev-
alence of HLA-B*51 among nine cohorts worldwide and that this
mutation is selected by Pol283-8(TAFTIPSI: TI8)-specific, HLA-
B*51:01-restricted CTLs (15). Of these cohorts, a Japanese one
showed the highest frequency of the I135X mutation in HLA-
B*51:01 negatives (66% in a Japanese cohort and 11 to 29% in
other cohorts). This finding may be explained by the fact that the
Japanese cohort has the highest prevalence of HLA-B*51:01
among these cohorts. Another possibility is that this mutation is
selected by HIV-1-specific CTLs restricted by other HLA alleles,
which are highly frequent among Japanese individuals but infre-
quent in or absent from other populations. To clarify the latter
possibility, we first analyzed the association of the I135Xmutation
with other HLA class I alleles in a Japanese cohort and found this
mutation also to be associatedwithHLA-B*52:01.We next sought
to identify an HLA-B*52:01-restricted CTL epitope including
RT135 and found that both HLA-B*51:01 and -B*52:01 can pres-
ent the same epitope, Pol283-8. Using population level analyses of
Japanese and Caucasian cohorts, we identifiedHLA-B*51:01- and
HLA-B*52:01-specific polymorphisms at RT codon 135 (position
8 of this epitope) and characterized differential pathways of escape
between these two alleles. In addition, we assessed the in vitro
ability of HLA-B*52:01- and HLA-B*51:01-restricted CTLs to se-
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lect I135X mutants and elucidated the crystal structure of the
HLA-B*52:01-Pol283-8 peptide complex.
MATERIALS AND METHODS
Patients. Two hundred fifty-seven chronically HIV-1-infected, antiretro-
viral-naïve Japanese individuals were recruited for the present study,
which was approved by the ethics committees of Kumamoto University
and the National Center for Global Health and Medicine, Japan. Written
informed consent was obtained from all subjects according to the Decla-
ration of Helsinki.
In addition, HLA-associated immune selection pressure at RT codon
135 was investigated in the International HIV Adaptation Collaborative
(IHAC) cohort, comprising1,200 chronically HIV-infected, antiretro-
viral-naïve individuals fromCanada, the United States, andWestern Aus-
tralia (19). Themajority of the IHACparticipantswereCaucasian, and the
HIV subtype distribution was95% subtype B.
HIV-1 clones.An infectious proviral clone ofHIV-1, pNL-432, and its
mutant form pNL-M20A (containing a substitution of Ala for Met at
residue 20 ofNef) were previously reported (29). Pol283-8mutant viruses
(Pol283-8L, -8T, -8V, and 8R) were previously generated on the basis of
pNL-432 (15, 28).
Generation of CTL clones. Pol283-8-specific, HLA-B*52:01-re-
stricted CTL clones were generated fromHIV-1-specific, bulk-cultured T
cells by limiting dilution in U-bottom 96-well microtiter plates (Nunc,
Roskilde, Denmark). Each well contained 200 l of the cloning mixture
(about 1 106 irradiated allogeneic peripheral blood mononuclear cells
(PBMCs) from healthy donors and 1 105 irradiated C1R-B*52:01 cells
prepulsed with the corresponding peptide at 1 M in RPMI 1640 supple-
mented with 10% human plasma and 200 U/ml human recombinant
interleukin-2).
Intracellular cytokine staining (ICS) assay. PBMCs from HIV-1-se-
ropositive HLA-B*52:01HLA-B*51:01 individuals were cultured with
each peptide (1 M). Two weeks later, the cultured cells were stimulated
with C1R-B*52:01 cells or those prepulsed with Pol283-8 peptide (1 M)
for 60 min, and then they were washed twice with RPMI 1640 containing
10% fetal calf serum (RPMI 1640-10% FCS). Subsequently, brefeldin A
(10 g/ml) was added. After these cells had been incubated for 6 h, they
were stained with an anti-CD8 monoclonal antibody (MAb; Dako Cor-
poration, Flostrup, Denmark), fixed with 4% paraformaldehyde, and
then permeabilized with permeabilization buffer. Thereafter, the cells
were stained with an anti-gamma interferon (IFN-) MAb (BD Biosci-
ence). The percentage of CD8 cells positive for intracellular IFN- was
analyzed by using a FACS-Cant II (BDBiosciences, San Jose, CA). All flow
cytometric data were analyzed with FlowJo software (Tree Star, Inc., Ash-
land, OR).
Identification of 11-mer peptide recognized by HLA-B*52:01-re-
stricted CD8 T cells. We identified an 11-mer peptide recognized by
HLA-B*52:01-restricted CD8 T cells as follows. We stimulated PBMCs
from a chronically HIV-1-infected HLA-B*52:01 donor (KI-069) with a
peptide cocktail including overlapping 17-mer peptides covering RT135
and cultured the cells for 14 days. The cells in bulk culture were as-
sessed by performing an ICS assay for C1R-HLA-B*52:01 cells pre-
pulsed with each of these 17-mer peptides. The bulk-cultured cells
recognized the target cells prepulsed with two of the 17-mer peptides
assessed, Pol17-47 (KDFRKYTAFTIPSINNE) and Pol17-48 (TAFTIPSI
NNETPGIRT). Further analysis with 11-mer overlapping peptides cover-
ing the Pol17-48 sequence showed that these bulk-cultured cells recog-
nized the target cells prepulsed with Pol11-142 (TAFTIPSINNE) but not
those prepulsed with Pol11-143 (FTIPSINNETP).
Assay of cytotoxicity of CTL clones to target cells prepulsedwith the
epitope peptide or infected with a vaccinia virus–HIV-1 recombinant.
The cytotoxicity of Pol283-8-specific, HLA-B*52:01-restricted CTL
clones to C1R cells expressing HLA-B*52:01 (C1R-B*52:01), which were
previously generated (30), and prepulsed with peptide or infected with a
vaccinia virus-HIV-1Gag/Pol recombinant was determined by the stan-
dard 51Cr release assay described previously (31). In brief, the infected
cells were incubatedwith 150CiNa2
51CrO4 in saline for 60min and then
washed three times with RPMI 1640 medium containing 10% newborn
calf serum. Labeled target cells (2 103/well) were added to each well of a
U-bottom 96-well microtiter plate (Nunc, Roskilde, Denmark) with the
effector cells at an effector-to-target (E/T) cell ratio of 2:1. The cells were
then incubated for 6 h at 37°C. The supernatants were collected and ana-
lyzedwith a gamma counter. Spontaneous 51Cr release was determined by
measuring the number of counts per minute (cpm) in supernatants from
wells containing only target cells (cpm spn). Maximum 51Cr release was
determined by measuring the cpm in supernatants from wells containing
target cells in the presence of 2.5% Triton X-100 (cpmmax). Specific lysis
was defined as (cpmexp cpm spn)/(cpmmax cpm spn) 100, where
cpm exp is the number of cpm in the supernatant in the wells containing
both target and effector cells.
Enzyme-linked immunospot (ELISPOT) assay. Cryopreserved
PBMCs of chronically HIV-1-infected HLA-B*52:01 individuals were
plated in 96-well polyvinylidene plates (Millipore, Bedford, MA) that had
been precoated with 5 g/ml anti-IFN- MAb 1-DIK (Mabtech, Stock-
holm, Sweden). The appropriate amount of each peptide (100 or 10 nM)
was added in a volume of 50 l, and then PBMCs were added at 1 105
cells/well in a volume of 100l. The plates were incubated for 40 h at 37°C
in 5%CO2 and then washed with phosphate-buffered saline (PBS) before
the addition of biotinylated anti-IFN-MAb (Mabtech) at 1g/ml. After
the plates had been incubated at room temperature for 100 min and then
washed with PBS, they were incubated with streptavidin-conjugated alka-
line phosphatase (Mabtech) for 40 min at room temperature. Individual
cytokine-producing cells were detected as dark spots after a 20-min reac-
tion with 5-bromo-4-chloro-3-indolylphosphate and nitroblue tetrazo-
lium by using an alkaline phosphatase-conjugate substrate (Bio-Rad,
Richmond, CA). The spots were counted by an Eliphoto-Counter (Mi-
nerva Teck, Tokyo, Japan). PBMCs without peptide stimulation were
used as a negative control. Positive responses were defined as those greater
than the mean of the negative-control wells plus 2 standard deviations
(SD) (the number of spots in wells without peptides).
HIV-1 replication suppression assay. The ability of HIV-1-specific
CTLs to suppressHIV-1 replicationwas examined as previously described
(32). CD4 T cells isolated from PBMCs derived from an HIV-1-serone-
gative individual with HLA-B*52:01, HLA-B*51:01, or both were cul-
tured. After the cells had been incubatedwith the desiredHIV-1 clones for
4 h at 37°C, they were washed three times with RPMI 1640-10% FCS
medium. The HIV-1-infected CD4 T cells were then cocultured with
Pol283-8-specific CTL clones. From day 3 to day 7 postinfection, culture
supernatants were collected and the concentration of p24 antigen (Ag) in
themwasmeasured by use of an enzyme-linked immunosorbent assay kit
(HIV-1 p24 Ag ELISA kit; ZeptoMetrix).
HLA stabilization assay with RMA-S cells expressing HLA-B*52:01
or HLA-B*51:01. The peptide-binding activity of HLA-B*52:01 or HLA-
B*51:01 was assessed by performing an HLA stabilization assay with
RMA-S cells expressingHLA-B*52:01 (RMA-S-B*52:01) orHLA-B*51:01
(RMA-S-B*51:01) as described previously (33). Briefly, RMA-S-B*51:01
and RMA-S-B*52:01 cells were cultured at 26°C for 16 to 24 h. The cells
(2 105) in 50 l of RPMI 1640 supplemented with 5% FCS (RPMI–5%
FCS) were incubated at 26°C for 3 h with 50l of a solution of peptides at
103 to 107 M and then at 37°C for 3 h. After having been washed with
RPMI–5% FCS, the cells were incubated for 30 min on ice with an appro-
priate dilution of TP25.99MAb. After two washings with RPMI–5% FCS,
they were incubated for 30 min on ice with an appropriate dilution of
fluorescein isothiocyanate (FITC)-conjugated anti-mouse Ig antibodies.
Finally, the cells were washed three times with RPMI–5% FCS and the
fluorescence intensity of the cells was measured by the FACS-Cant II.
Relative mean fluorescence intensity (MFI) was calculated by subtracting
the MFI of cells not peptide pulsed from that of the peptide-pulsed ones.
Sequencingof plasmaRNA.Viral RNAwas extracted from theplasma
of chronically HIV-1-infected Japanese individuals by using a QIAamp
Yagita et al.
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Mini Elute Virus spin kit (Qiagen). cDNA was synthesized from the RNA
with Superscript II and random primer (Invitrogen). We amplified HIV
RT and integrase sequences by nested PCR with RT-specific primers 5=-
CCAAAAGTTAAGCAATGGCC-3= and 5=-CCCATCCAAAGGAATGG
AGG-3= or 5=-CCTTGCCCCTGCTTCTGTAT-3= for the first-round
PCR and 5=-AGTTAGGAATACCACACCCC-3= and 5=-GTAAATCCCC
ACCTCAACAG-3= or 5=-AATCCCCACCTCAACAGAAG-3= for the sec-
ond-round PCR and integrase-specific primers 5=-ATCTAGCTTTGCAG
GATTCGGG-3= and 5=-CCTTAACCGTAGTACTGGTG-3= or 5=-CCTG
ATCTCTTACCTGTCC-3= for the first-round PCR and 5=-AAAGGTCT
ACCTGGCATGGG-3= or 5=-TTGGAGAGCAATGGCTAGTG-3= and 5=-
AGTCTACTTGTCCATGCATGGC-3= for the second-round PCR. PCR
products were sequenced directly or cloned with a TOPO TA cloning kit
(Invitrogen) and then sequenced. Sequencing was done with a BigDye
Terminator v1.1. cycle sequencing kit (Applied Biosystems) and analyzed
by an ABI PRISM 310 Genetic Analyzer.
Statistical analysis with phylogenetically corrected odds ratios.
Strength of selection was measured by using a phylogenetically corrected
odds ratio as previously described (19). Briefly, the odds of observing a
given amino acid (e.g., 135V)wasmodeled as P/(1 P) (aX) (b
T), where P is the probability of observing 135V in a randomly selected
individual, X is a binary (0/1) variable representing whether or not an
individual expresses the HLA allele in question (e.g., B*52:01), and T
equals 1 if the transmitted/founder virus for that individual carried 135V
and1 otherwise. Because the transmitted/founder virus is unknown, we
averaged over all possibilities by using weights informed by a phylogeny
that was constructed from the RT sequences of all of the individuals in the
study. The parameters a and b were determined by using iterative maxi-
mum-likelihood methods. The maximum-likelihood estimate of a is an
estimate of the natural logarithm of the odds ratio of observing 135V in
individuals expressingX versus individuals not expressingX, conditioned
on the individuals’ (unobserved) transmitted/founder virus. P values are
estimated by using a likelihood ratio test that compares the above model
to a null model in which a equals 0.
To compare the odds of selection between two cohorts, we modified
the phylogenetically corrected logistic regression model to include a co-
hort term,ZXY, whereX is theHLA allele, andY is a 0/1 variable that
indicates cohort membership, yielding P/(1 P) (a X) (b T)
(c  Z), as previously described (19, 34). A P value testing if the odds of
escape are different in the two cohorts was estimated by using a likelihood
ratio test that compared this model to a null model where c equals 0.
Generation of HLA class I tetramers.HLA class I-peptide tetrameric
complexes (tetramer) were synthesized as described previously (31, 35).
The Pol283-8 peptide was used for the refolding ofHLA-B*51:01 orHLA-
B*52:01 molecules. Phycoerythrin (PE)-labeled streptavidin (Molecular
Probes) was used for generation of the tetramers.
Tetramer binding assay.HLA-B*51:01-restricted and HLA-B*52:01-
restricted CTL clones were stained at 37°C for 30min with PE-conjugated
HLA-B*51:01-tetramer and HLA-B*52:01-tetramer, respectively, at con-
centrations of 5 to 1,000 nM. After two washes with RPMI 1640 medium
supplemented with 10% FCS (RPMI 1640–10% FCS), the cells were
stained with FITC-conjugated anti-CD8MAb at 4°C for 30min, followed
by 7-amino-actinomycin D at room temperature for 10 min. After two
more washes with RPMI 1640–10% FCS, the cells were analyzed by the
FACS-Cant II flow cytometer. The tetramer concentration that yielded
the half-maximal MFI (the EC50) was calculated by probit analysis.
Crystallization, data collection, and structure determination. Solu-
ble HLA-B*52:01 (with beta-2microglobulin and peptide TAFTIPSI) was
prepared as described above. Prior to crystallization trials, HLA-B*52:01
was concentrated to a final concentration of 20 mg ml1 in 20 mM Tris-
HCl (pH 8.0) buffer containing 250 mM NaCl. This was done with a
Millipore centrifugal filter device (Amicon Ultra-4, 10-kDa cutoff; Milli-
pore). Screening for crystallization was performed with commercially
available polyethylene glycol (PEG)-based screening kits, PEGs and PEGs
II suites (Qiagen). Thin needle crystals were observed from PEGs II suite
23 (0.2 M sodium acetate, 0.1 M HEPES [pH 7.5], and 20% PEG 3000).
Several conditions were further screened by the hanging-drop method
with 24-well VDX plates (Hampton Research) by mixing 1.5 l protein
solution and 1.5 l reservoir to be equilibrated against reservoir solution
(0.5 ml) at 293 K. Best crystals were grown from macro seeding with the
initial crystals obtainedwith 0.2M sodium acetate, 0.1MBis Tris propane
[pH 7.5], and 20% PEG 3350.
The data set was collected at beamline BL41XUof SPring-8with Rayo-
nix charge-coupled device detector MX225HE. Prior to diffraction data
collection, crystals were cryoprotected by transfer to a solution containing
25% (vol/vol) glycerol and incubation in it for a few seconds, followed by
flash cooling. The data sets were integrated with XDS (36) and then
merged and scaled by using Scala (37). HLA-B*52:01 crystals belonged to
space group P212121, with unit cell parameters a 69.0 Å, b 83.3 Å, and
c 170.3 Å. Based on the values of theMatthews coefficient (VM) (38), we
estimated that therewere two protomers in the asymmetric unit with aVM
value of 1.37A3/Da (Vsolv 10.5%). For details of the data collection and
processing statistics, see Table S1 in the supplemental material.
The structure was solved by the molecular replacement method with
Molrep (39). The crystal structure of HLA-B*51:01 (PDB ID: 1E28) was
used as a search model. Structure refinement was carried out by using
Refmac5 (40) and phenix (41). The final model was refined to an Rfree
factor of 34.7% and an R factor of 29.5% with a root mean square devia-
tion of 0.014 Å in bond length and 1.48° in bond angle for all reflections
between resolutions of 38.8 and 3.1 Å. Table S1 in the supplemental ma-
terial also presents a summary of the statistics for structure refinement.
The stereochemical properties of the structure were assessed by Procheck
(42) and COOT (43) and showed no residues in the disallowed region of
the Ramachandran plot.
Protein structure accession number. Atomic coordinates and struc-
ture factors for HLA-B*52:01 have been deposited in the Protein Data
Bank under accession code 3W39.
RESULTS
Association of I135X variants with HLA-B*52:01. To clarify the
possibility that CTLs restricted by other HLA alleles select the
I135X mutation, we investigated the association between other
HLA alleles and this mutation in 257 Japanese individuals chron-
ically infected with HIV-1. We found an association of HLA-
B*52:01 with the I135X variant, though this association was
weaker than that with HLA-B*51:01 (phylogenetically corrected
ln odds ratio [lnOR] of 11.76 [P 8.77 104] for B*52:01 versus
an lnOR of 40.0 [P 5.78 1012] for B*51:01; Table 1).We also
analyzed the effects of HLA-B*52:01 and HLA-B*51:01 in chron-
ically HIV-1-infected Japanese individuals, excluding HLA-B*51:
01 andHLA-B*52:01 individuals, respectively, and found a sig-
nificant association between HLA-B*52:01 and I135X variants
among 200 HLA-B*51:01-negative individuals with chronic
HIV-1 infection (P 4.7 104; see Fig. S1A in the supplemental
material) and that of HLA-B*51:01 with the variants in 202 HLA-
B*52:01-negative ones (P  5.3  108; see Fig. S1B in the sup-
plemental material). These results together imply that HLA-B*52:
01-restricted CTLs selected this mutation.
Identification of HLA-B*52:01-restricted, Pol283-specific
CTLs. To identify the HLA-B*52:01-restricted HIV-1 epitope in-
cluding RT135, we first investigatedwhether overlapping peptides
covering RT135 could elicit CD8 T cells specific for these pep-
tides in chronically HIV-1-infected individuals. We identified
CTLs recognizing the Pol11-142 (TAFTIPSINNE) peptide in a
chronically HIV-1-infected HLA-B*52:01 donor, KI-069 (see
Materials and Methods). Since the C terminus of HLA-B*52:01-
binding peptides is known to be a hydrophobic residue (30, 44),
we speculated that TAFTIPSI (Pol283-8) was the epitope peptide.
Different Selection Pattern of RT135 Mutant
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Indeed, bulk-cultured T cells that had been cultured for 2 weeks
after stimulation with Pol17-48 recognized C1R-B*52:01 cells
prepulsed with Pol283-8 peptide at a much lower concentration
than those incubated with the Pol11-142 peptide (Fig. 1A),
strongly suggesting that Pol283-8 is an epitope recognized by
HLA-B*52:01-restricted CTLs. These findings were confirmed by
ELISPOT assay with PBMCs from twoHLA-B*52:01 individuals
chronically infected with HIV-1 (Fig. 1B). To clarify whether this
peptide was processed and presented by HLA-B*52:01, we inves-
tigated the killing activity of bulk-cultured T cells against HLA-
B*52:01 target cells infected with a vaccinia virus–HIV-1 Gag/
Pol recombinant. They killed target cells infected with this
recombinant but not those infected with wild-type vaccinia virus
(Fig. 1C), indicating that the Pol283-8 peptide was presented by
TABLE 1 HLA-B*52:01 and HLA-B*51:01 association with variation at RT135 in Japanese and Caucasian cohorts
HLA class I allele RT135 target variable
PlyloLORa Within-cohort P value
P value comparing cohortsJapanese IHAC Japanese IHAC
B*51:01 T 13.70 4.53 4.66 106 1.70 1035 0.042
B*52:01 T 9.77 1.25 0.464 2.04 103 0.62
B*51:01 I 40.00 5.71 5.78 1012 1.58 1051 0.052
B*52:01 I 11.76 3.06 8.77 104 2.95 105 0.52
B*51:01 V 9.76 8.52 0.884 0.41 0.85
B*52:01 V 12.21 10.15 0.076 1.82 103 0.037
B*51:01 R 12.08 13.02 0.038 2.36 103 0.42
B*52:01 R 0.26 8.37 0.423 0.469 0.89
B*51:01 L 0.89 3.21 1 0.038 0.17
B*52:01 L 0.56 3.61 1 0.231 0.29
B*51:01 K 0.71 40.00 1 0.53 0.99
B*52:01 K 0.69 40.00 1 0.779 0.99
B*51:01 M 7.76 12.00 0.894 2.10 104 0.34
B*52:01 M 11.09 40.00 0.034 0.517 0.12
a PlyloLOR, phylogenetically corrected lnOR.
FIG 1 Identification of HLA-B*52:01-restricted Pol epitope. (A) Identification of the epitope peptide recognized byHLA-B*52:01-restricted CD8 T cells. Bulk
T cells were cultured for 2 weeks after stimulation with the Pol17-48 peptide, and then the recognition of C1R-HLA-B*52:01 cells prepulsed with Pol17-48,
Pol11-142, or Pol283-8 peptidewas assessed by ICS assay. (B) Pol283-8 peptide recognition byT cells ex vivo. Recognition of the Pol17-48, Pol11-142, or Pol283-8
peptide by PBMCs from two HLA-B*52:01 individuals chronically infected with HIV-1 (KI-037 and KI-069) was analyzed by ELISPOT assay. A 100 nM
concentration of each peptide was used. (C) Killing activity of Pol283-specific, HLA-B*52:01-restricted CD8 T cells against cells infected with a vaccinia
virus–HIV-1 Gag/Pol recombinant. The killing activities of bulk-cultured T cells stimulated with Pol11-142 against target cells infected with a vaccinia virus–
HIV-1 Gag/Pol recombinant (Gag/Pol) and against those infected with wild-type vaccinia virus (V.V. WT) are shown. (D) Binding of Pol283-8 peptide to
HLA-B*52:01. Binding ability was measured by performing the HLA class I stabilization assay with RMA-S-B*52:01. RMA-S-B*51:01 cells were used as control
cells for the Pol283-8 peptide.
Yagita et al.
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HLA-B*52:01.We analyzed the binding of the Pol283-8 peptide to
HLA-B*52:01 by using the HLA stabilization assay. The results
demonstrated that this peptide bound to HLA-B*52:01 (Fig. 1D).
These results together indicate that the Pol283-8 epitope can
therefore be presented by both HLA-B*51:01 and HLA-B*52:01.
We investigated whether Pol283-8-specific CD8 T cells were
elicited predominantly in chronically HIV-1-infected HLA-B*52:
01HLA-B*51:01 individuals. PBMCs from 14 of these individ-
uals were analyzed by ICS assay with Pol283-8 peptide-stimulated
culture cells, as well as by ELISPOT assay. The results of the ICS
assay showed that 7 of these 14 HLA-B*52:01 HLA-B*51:01
patients had Pol283-specific CD8 T cells, whereas those of the
ELISPOT assay with ex vivo PBMCs revealed that Pol283-specific
CD8 T cells were detected in only four individuals (Table 2).
These results suggest that the three individuals in whom the spe-
cific CTLs were detected by the ICS assay but not by the ELISPOT
assay may have memory T cells. These results together indicate
that Pol283-8 was recognized as an HLA-B*52:01-restricted im-
munodominant epitope in the HLA-B*52:01 individuals and
support the idea that the I135X mutation was selected by HLA-
B*52:01-restricted, Pol283-8-specific CD8 T cells.
Strong ability of HLA-B*52:01-restricted, Pol283-8-specific
CD8 T cells to suppress HIV-1 replication. A previous study
showed that HLA-B*51:01-restricted, Pol283-8-specific T cells
have a strong ability to kill HIV-1-infected target cells and to sup-
press HIV-1 replication (31). Therefore, we expected that the
HLA-B*52:01-restricted T cells also would have this strong ability.
We generated HLA-B*52:01-restricted, Pol283-8-specific T cell
clones and investigated their ability to kill peptide-pulsed or HIV-
1-infected target cells. Clone 1E1 effectively killed C1R-B*52:01
cells prepulsed with the Pol283-8 peptide (Fig. 2A) and NL-432-
infected CD4 T cells from an HLA-B*52:01 individual (Fig.
2B). Additional T cell clones also showed strong killing activity
against NL-432-infected HLA-B*52:01 CD4 T cells (data not
shown). In addition, we investigated the ability of these CTL
clones to suppress HIV-1 replication. CD4 T cells derived from
anHLA-B*52:01 individual were infected withNL-432 orM20A
mutant virus, the latter of which has an amino acid substitution at
position 20 ofNef and lacks the ability to downregulate the surface
expression of HLA-A and -B molecules (Fig. 2C). Representative
data on the 1E1 clone and summary data on four clones are shown
in Fig. 2D and E, respectively. These CTL clones strongly sup-
pressed the replication of both the NL432 and M20A mutant vi-
ruses, indicating that the HLA-B*52:01-restricted CTLs had a
strong ability to suppress HIV-1 replication, as was the case with
the HLA-B*51:01-restricted ones.
Recognition of I135X mutations by Pol283-8-specific, HLA-
B*52:01-restricted CTLs. Four mutations (8T, 8L, 8R, and 8V)
were observed predominantly at RT135 in chronically HIV-1-in-
fected HLA-B*52:01 individuals (Fig. 3). These mutations may
have been selected by Pol283-8-specific, HLA-B*52:01-restricted
CTLs in these patients. We therefore investigated the ability of
HLA-B*52:01-restricted CTLs to suppress the replication of these
mutant viruses in vitro. The CTL clones failed to suppress the
replication of the 8L, 8T, or 8R mutant, though they weakly sup-
pressed that of the 8V virus at an E/T cell ratio of 1:1 (Fig. 4A).
These results support the idea that these variants were escape mu-
tations from the HLA-B*52:01-restricted CTLs. To clarify the
mechanism by which the CTL clones failed to suppress the repli-
cation of these mutant viruses, we investigated the CTL clones for
recognition of C1R-B*52:01 cells prepulsed with the mutant pep-
tides. The CTL clones effectively recognized the 8V peptide at the
same level as the wild-type peptide and the 8T and 8L peptides at
less than that of thewild-type one, whereas they failed to recognize
the 8R peptide (Fig. 4B). An ELISPOT assay with ex vivo PBMCs
from KI-069 showed that Pol283-8-specific CTLs effectively rec-
ognized the 8I and 8V variants but not the other three mutant
peptides (Fig. 4C), suggesting that Pol283-8-specific CTLs failed
to recognize the 8T, 8L, and 8R peptides in vivo. The lack of rec-
ognition of these mutants by CTLsmay be attributable to a failure
of T cell receptor (TCR) recognition, the inability of the peptide to
bind to HLA-B*52:01, and/or disruption of the processing of the
epitope in HIV-1-infected cells.
Different pattern of RT135 mutation selection by two HLA
alleles.As described above, HLA-B*51:01 andHLA-B*52:01 were
associated with I135X in a Japanese population in which the preva-
lence of HLA-B*51:01 and B*52:01 alleles is relatively high (21.9
and 21.1%, respectively). In a Japanese cohort, out of the five
TABLE 2 Pol283-8-specific CD8 T cells in chronically HIV-1-infected, HLA-B*52:01 individuals
Patient ID HLA class I alleles
No. of CD4
cells/l
No. of CD8
cells/l
Viral load (no.
of copies/ml)
Antiretroviral
therapy
Relative IFN-
/CD8%
in ICC assay
No. of spots/106
PBMCs in
ELISPOTa assay
KI-037 A*24:02/ B*52:01/40:02 465 973 76,000  64.1 150
KI-090 A*24:02/ B*52:01/55:01 606 511 50  40.2 80
KI-106 A*24:02/33:03 B*52:01/07:01 433 890 50  1.4 79
KI-126 A*24:02/31:01 B*52:01/40:01 465 NTb 36,000  60.4 79
KI-130 A*24:02/ B*52:01/07:02 351 1,275 14,000  0.0 79
KI-167 A*24:02/ B*52:01/54:01 455 909 26,000  0.0 79
KI-067 A*24:02/ B*52:01/48:01 234 1,198 89,000  10.9 79
KI-071 A*24:02/31:01 B*52:01/40:06 292 1,134 48,000  0.7 79
KI-076 A*02:01/24:01 B*52:01/40:01 136 252 14,000  61.0 80
KI-114 A*02:01/24:01 B*52:01/27:04 416 463 50  0.1 79
KI-056 A*24:02/ B*52:01/40:02 290 844 8,200  -0.1 79
KI-108 A*24:02/ B*52:01/ 373 481 NT  1.0 79
KI-028 A*24:02/26:01 B*52:01/48:01 1,351 811 50  0.5 79
KI-069 A*24:02/ B*52:01/40:06 448 1,631 4,400  18.1 790
a More than the mean number of negative-control spots 2 SD was defined as a positive response (positive response,79 spots).
b NT, not tested.
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amino acid mutations that can be generated by a one-nucleotide
mutation from Ile, the T mutation was strongly associated with
the presence of HLA-B*51:01 (P  4.66  106), whereas HLA-
B*52:01 was associated not with any single amino acid substitu-
FIG 2 Abilities of HLA-B*52:01-restricted, Pol283-8-specific CD8 T cell clones to kill HIV-1-infected CD4 T cells and to suppress HIV-1 replication. (A) Killing
activity of an HLA-B*52:01-restricted, Pol283-8-specific CD8 T cell clone against C1R-B*52:01 cells prepulsed with Pol283-8 peptides. The activity of an HLA-B*52:
01-restricted, Pol283-8-specific CD8 T clone, 1E1, to kill C1R-B*52:01 cells was measured by performing a 51Cr-release assay. (B) Killing activity of HLA-B*52:01-
restricted, Pol283-8-specific CD8 T cell clone 1E1 against CD4 T cells infected with HIV-1. The ability of the clone to kill CD4 T cells infected with NL-432 was
measuredbyperforminga51Cr-releaseassay. (C)DownregulationofHLA-B*52:01 inHIV-1-infectedCD4Tcells.CD4Tcellsderived fromanHLA-B*52:01donor
(HLA-A*11:01/A*24:02, HLA-B*52:01/B*52:01, andHLA-C*12:02/C*14:02) were infected with NL-432 and then cultured for 4 days. The cultured CD4 T cells were
stained with anti-p24 Ag and TU¨109 anti-Bw4 MAbs. (D) Ability of an HLA-B*52:01-restricted, Pol283-8-specific CD8 T cell clone to suppress the replication of
NL-432 and M20A mutant viruses. Suppressing ability was measured at four different E/T cell ratios (1:1, 0.1:1, 0.01:1, and 0.001:1). HIV-1-infected HLA-B*52:01
CD4Tcells were coculturedwith anHLA-B*52:01-restricted, Pol283-8-specificCTL clone or anHLA-mismatchedCTL clone at various E/T cell ratios.HIV-1p24Ag
levels in the supernatant weremeasured on day 6 postinfection. (E) Summary of the ability ofHLA-B*52:01-restricted, Pol283-8-specific CD8T cell clones (n 4) to
suppress the replication of Nl-432 andM20Amutant viruses at four different E/T cell ratios.
FIG 3 Amino acid variation at RT135 in Japanese individuals. (A) Frequency
of the amino acid at RT135 in 51 HLA-B*51:01 HLA-B*52:01, 49 HLA-
B*51:01 HLA-B*52:01, and 151 HLA-B*51:01 HLA-B*52:01 Japanese
subjects. (B) Frequency of the amino acid at RT135 in 131 HLA-B*51:01
HLA-B*52:01, 26 HLA-B*51:01 HLA-B*52:01, and 1195 HLA-B*51:01
HLA-B*52:01 subjects in three predominantly Caucasian cohorts fromCan-
ada, the United States, and Western Australia (IHAC).
FIG 4 Ability of HLA-B*52:01-restricted, Pol283-8-specific CD8 T cell
clones to suppress the replication of four mutant viruses. (A) Ability of an
HLA-B*52:01-restricted, Pol283-8-specific CD8 T cell clone to suppress the
replication of four (8L, 8T, 8R, and 8V) mutant viruses and NL-432. The
abilities of an HLA-B*52:01-restricted, Pol283-8-specific CD8 T cell clone
and an HLA-A*1101-restricted Nef73-specific T cell clone to suppress the
replication of these viruses were measured at an E/T cell ratio of 1:1 on days 3
to 6. W/O, without. (B) Recognition by an HLA-B*52:01-restricted, Pol283-
8-specific CD8 T cell clone of C1R-B*52:01 cells prepulsed with any one of
the four mutant epitope peptides or the wild-type (WT) peptide (8I). (C)
Recognition of mutant epitope peptides by ex vivo Pol283-8-specific CTLs.
The recognition of the Pol283-8 peptide (WT) or the mutant epitope peptide
by PBMCs from KI-069 was analyzed by ELISPOT assay.
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tion but only with the non-Imutation (P 8.77 104, Table 1).
The distribution of amino acid variations at RT135 in the HLA-
B*51:01 HLA-B*52:01 Japanese subjects was different from
that in the HLA-B*51:01 HLA-B*52:01 ones (Fig. 3). These
results suggest that the HLA-B*51:01-restricted CTLs strongly se-
lected the 135T mutation but that the HLA-B*52:01-restricted
ones selected a variety of different amino acids at this position in
Japanese individuals.
We also analyzed the association of I135X mutations with
HLA-B*52:01 and HLA-B*51:01 in three predominantly Cauca-
sian cohorts from Canada, the United States, and Western Aus-
tralia (International HIV Adaptation Collaborative [IHAC]) (19)
comprising 1,200 subjects (Table 1). HLA-B*51:01 was very
strongly associated with the I135X mutation (lnOR of 5.71; P 
1.58  1051). Although only 2.1% of the IHAC cohort subjects
expressed HLA-B*52:01, this allele was also associated with I135X
(lnOR of 3.06; P  2.95  105). The T mutation was strongly
associated with HLA-B*51:01 (P 1.70 1035), whereas the T
and V mutations were weakly associated with HLA-B*52:01
(0.0005 P  0.005). Thus, these results showed a similar selec-
tion of RT135 mutations by HLA-B*52:01 in the predominantly
Caucasian cohort, despite a substantially lower frequency ofHLA-
B*52:01. The magnitude of the strength of selection by HLA-
B*52:01 and HLA-B*51:01 on RT135 did not differ significantly
between the two cohorts (Table 1). These results indicate that
HLA-B*51:01 strongly selected 135T but that HLA-B*52:01 se-
lected a variety of substitutions at this site (designated I135X) in
both the Japanese and non-Japanese cohorts.
Comparison of TCR affinity and abilities of HLA-B*51:01-
restricted andHLA-B*52:01-restricted CTLs to suppress HIV-1
replication. We investigated the TCR affinity of HLA-B*51:01-
restricted and HLA-B*52:01-restricted CTL clones by using te-
tramers of the HLA-B*51:01-Pol283 peptide and the HLA-B*52:
01-Pol283 peptide complex (HLA-B*51:01 and HLA-B*52:01
tetramers, respectively). The TCR affinity of these CTL clones was
compared in terms of EC50. The EC50 of the HLA-B*51:01-re-
stricted CTL clones was significantly lower than that of the HLA-
B*52:01-restricted CTL clones (Fig. 5A), suggesting that the for-
merCTL clones hadTCRswith a higher affinity for the ligand than
those of the latter clones. These results imply that the HLA-B*51:
01-restricted CTL clones could recognize the HIV-1-infected tar-
gets more effectively than HLA-B*52:01-restricted ones.
Since CD4 T cells derived from an HLA-B*52:01 homozy-
gous individual were used in the experiment shown in Fig. 2D and
E, the ability of the HLA-B*52:01-restricted CTL clones to sup-
press the replication of NL-432 may have been overestimated. To
evaluate and compare the abilities of HLA-B*51:01-restricted and
HLA-B*52:01-restricted CTL clones to suppress the replication of
NL-432, we used CD4 T cells from individuals expressing HLA-
B*51:01/B*52:01, HLA-B*51:01/B*52:01, or HLA-B*51:
01/B*52:01 (Fig. 5B). TwoHLA-B*51:01-restrictedCTL clones
strongly inhibited the replication of HIV-1 in cultures of NL-432-
infected HLA-B*51:01/B*52:01 CD4 T cells but not in those
of HLA-B*51:01/B*52:01 cells, whereas two HLA-B*52:01-re-
stricted CTL clones strongly inhibited the replication of HIV-1 in
cultures of NL-432-infected HLA-B*51:01/B*52:01 CD4 T
cells but not in those of HLA-B*51:01/B*52:01 cells (Fig. 5B,
left and middle). The ability of the HLA-B*51:01-restricted CTL
clones to suppress the replication of HIV-1 was greater than that
of theHLA-B*52:01-restrictedCTL clones. This was confirmed by
the experiment with HLA-B*51:01/B*52:01 CD4 T cells
(Fig. 5B, right). Although bothHLA-B*51:01-restricted andHLA-
B*52:01-restricted CTL clones strongly inhibited the replication
ofHIV-1 in the cultures ofNL-432-infectedHLA-B*51:01/B*52:
01 CD4 T cells, the former clones exhibited a greater ability to
suppress the replication of HIV-1 than did the latter cells. These
results indicate that theHLA-B*51:01-restricted CTL clones had a
stronger ability to suppressHIV-1 replication than theHLA-B*52:
01-restricted clones. Taken together, both our in vitro and our in
vivo (population level HLA-association) data suggest that im-
mune pressure on RT135 by HLA-B*51:01-restricted T cells was
stronger than that imposed by HLA-B*52:01-restricted cells.
Structural basis of the difference in recognition between
HLA-B*52:01- and HLA-B*51:01-restricted CTLs. In order to
investigate the structural basis of the difference in recognition
between HLA-B*52:01- and HLA-B*51:01-restricted CTLs, we
performed a crystallographic study of the HLA-B*52:01 molecule
complexed with the Pol283-8 peptide. The recombinant HLA-
B*52:01 protein was crystallized, and by using the molecular re-
placement method, the three-dimensional structure of HLA-
B*52:01 complexed with the Pol283-8 peptide was successfully
determined. The crystal and statistical data are summarized in
Table S1 in the supplemental material. The overall structure and
peptide-binding mode were similar to those of HLA-B*51:01
complexedwith the same Pol283-8 peptide (Fig. 6A and B), which
FIG 5 Differences between HLA-B*51:01-restricted and HLA-B*52:01-re-
stricted CD8 T cell clones in TCR avidity and the ability to suppress HIV-1
replication. (A) TCR avidity of the HLA-B*51:01-restricted and HLA-B*52:
01-restricted CTL clones expressed as EC50. The ability of the TCRs of HLA-
B*51:01-restricted and HLA-B*52:01-restricted CTL clones to bind HLA-
B*51:01 tetramers and HLA-B*52:01 tetramers, respectively, was measured in
terms of the MFI of each CTL clone stained with the tetramers at concentra-
tions of 5 to 1,000 nM. (B) The ability of twoHLA-B*51:01-restricted and two
HLA-B*52:01-restricted CD8 T cell clones to suppress HIV-1 was measured
at six different E/T cell ratios (0.3:1, 0.1:1, 0.03:1, 0.01:1, 0.003:1, and 0.001:1).
CD4 T cells from individuals expressing HLA-B*51:01/B*52:01, HLA-
B*51:01/B*52:01, or HLA-B*51:01/B*52:01 were infected with NL-432
and then cocultured with a given Pol283-8-specific CTL clone or an HLA-
mismatched CTL clone. HIV-1 p24 Ag levels in the supernatant were mea-
sured on day 5 postinfection.
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we had previously reported (45). This finding explains the cross
presentation of this peptide by both HLA alleles. On the other
hand, there was a notable conformational difference in the N-ter-
minal region of the peptide between the two alleles (Fig. 6C and
D). The replacement of Phe67 of HLA-B*51:01 with Ser in HLA-
B*52:01 makes a local space, causing the N-terminal region of the
peptide (T1 and A2) to reside deeper in the peptide-binding
groove. Furthermore, the Gln63Glu mutation in HLA-B*52:01
affords a new interaction with the T1 residue of the peptide. These
changes would, to some extent, have hidden the side chains of T1
and A2 (flat surface) from the TCRs, which may have reduced
their interactions with TCRs on the HLA-B*52:01-restricted
CTLs. On the other hand, the conformation of the C-terminal
region of the peptide complexed with HLA-B*51:01 or HLA-
B*52:01 was similar, even though C-terminal Ile8 of the peptide
exhibited shallower penetration of the hydrophobic groove in the
case ofHLA-B*52:01 than in that ofHLA-B*51:01 (Fig. 6C and E).
These results may indicate that the relatively flat surface of the
N-terminal side of the peptide contributed to the lower affinity for
TCRs in the case of HLA-B*52:01.
DISCUSSION
HLA-B*52:01 and HLA-B*51:01 differ by only two residues, at
positions 63 and 67 (44). Substitutions at these residues affect the
formation of the B pocket in the peptide-binding pocket (45),
suggesting the possibility that HLA-B*52:01 has a peptide motif
different from that of HLA-B*51:01. Indeed, HLA-B*52:01-bind-
ing peptides have P2 primary anchors that are different from
HLA-B*51:01-binding ones (30, 46). Since the Pol283-8 epitope
carries Ala at its second position and Ile at the C terminus of the
peptide, it is likely that this peptidewould effectively bind toHLA-
B*51:01 but not toHLA-B*52:01. However, the results of theHLA
stabilization assay demonstrated that the Pol283-8 peptide did
effectively bind to HLA-B*52:01. Since the HLA-B*52:01-binding
peptide is known to have Pro as its preferred P2 anchor residue,
this peptide carryingAla at position 2may be capable of binding to
HLA-B*52:01. A previous study showed cross-recognition of allo-
reactive T cells between HLA-B*51:01 and HLA-B*52:01 (47, 48),
indicating that some self-peptides can be presented by both of
these HLA class I molecules. The findings on the crystal structure
FIG 6 Structural comparison of HLA-B*52:01 and HLA-B*51:01 molecules complexed with the Pol283-8 peptide. (A) Crystal structures of HLA 	1-	2
domains complexed with the Pol283-8 peptide (stick model) on the HLA-B*52:01 (green, yellow) and HLA-B*51:01 (cyan, cyan) complexes. This same
coloring also applies to panels B to E. (B) Pol283-8 peptide and interacting side chains on the HLA-B*52:01 complex. Hydrogen bonds are shown as blue
dotted lines. (C) Comparison of the Pol283-8 peptide conformations of HLA-B*52:01 and HLA-B*51:01 complexes. (D) N-terminal side of HLA-B*52:01
and HLA-B*51:01 complexes. (E) C-terminal side of HLA-B*52:01 and HLA-B*51:01 complexes. Surface presentation for the 	1-	2 domains is shown
in gray.
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of the HLA-B*52:01 molecule complexed with the Pol283-8 pep-
tide clarified that HLA-B*52:01 could bind to the peptide in a
fashion similar to but slightly different from that of HLA-B*51:01.
These findings support the presentation of the Pol283-8 peptide
by both HLA-B*52:01 and HLA-B*51:01.
Pol283-8-specific CD8 T cells were detected in 7 of 14 HLA-
B*52:01 HLA-B*51:01 individuals chronically infected with
HIV-1. A previous analysis showed that CD8 T cells specific for
this epitope are frequently detected in HLA-B*51:01 individuals
chronically infected with HIV-1 (49). These results, taken to-
gether, indicate that this epitope is immunodominant in both
HLA-B*51:01 and HLA-B*52:01 individuals. The analysis of
257 Japanese individuals revealed an association between HLA-
B*52:01 and a variety of nonconsensus residues at RT codon 135
(I135X). Specifically, variants 8T, 8L, 8R, and 8V predominated in
HLA-B*52:01 individuals, suggesting that these mutations had
been selected byHLA-B*52:01-restrictedCTLs. The viral suppres-
sion assay revealed that theHLA-B*52:01-restrictedCTLs failed to
suppress the replication of these mutant viruses. These results
support the idea that the I135X mutation can be selected by im-
mune pressure via Pol283-8-specific CTLs in HLA-B*52:01 in-
dividuals. Our previous studies showed that the 8L, 8T, and 8R
mutations affected the recognition by Pol283-8-specific, HLA-
B*51:01-restricted CTL clones (15, 28). These studies, together
with the present study, indicate that accumulation of 8L, 8T, and
8R mutations in the HIV-infected Japanese population may be
due to immune pressure by both HLA-B*52:01-restricted and
HLA-B*51:01-restricted CTLs. Our analysis of the crystal struc-
ture of the HLA-B*52:01-peptide complex demonstrated that po-
sition 8 of the Pol283-8 peptide was deeply packed into the
hydrophobic groove. Whereas the 8L, 8T, and 8R substitutions
likely had a relatively large effect on the structure of the com-
plex, the 8V mutation, resulting in only the deletion of the
small methyl group, caused only very limited changes. Thus,
the structural analysis supports the idea that the 8L, 8T, and 8R
mutations affected the TCR recognition of the peptide and/or
its binding to HLA-B*52:01.
The present study confirmed previous studies of nine world-
wide cohorts (15) and a Chinese cohort (50) that showed a strong
association of I135X with HLA-B*51:01. The I135Xmutation was
found in 58.3 and 27.6% of HLA-B*51:01HLA-B*52:01 Japa-
nese and predominantly Caucasian individuals, respectively (Ta-
ble 3), supporting greater population level accumulation of this
mutation in Japanese than in other cohorts. Since the Japanese
cohort included twice as many HLA-B*51:01 individuals as the
IHAC cohort (21.9% of Japanese and 9.4% of Caucasians in
IHAC), the difference in the I135X variant frequency between
these two cohorts would be driven, to a large extent, by the higher
HLA-B*51:01 prevalence in the former than in the latter. The
association of HLA-B*52:01 with this mutation was much weaker
than that of HLA-B*51:01 in both cohorts but still highly statisti-
cally significant (an lnOR of 11.7 [P  8.77  104] versus an
lnORof 40.0 [P 5.78 1012] in the Japanese cohort and an lnOR
of 3.06 [P 2.95 105] versus an lnORof 5.71 [P 1.58 1051]
in IHAC). Because of the relatively low B*52:01 frequency
(
2%) in IHAC, the effect of HLA-B*52:01 on the overall preva-
lence of I135X was relatively low in this cohort. In contrast, in the
Japanese cohort, where the HLA-B*52:01 prevalence was rela-
tively high (20%), this allele represents a major driving force
behind 135X selection in this cohort. Thus, selection pressure
from both HLA-B*51:01 and HLA-B*52:01 likely contributed to
the observed population level accumulation of I135X mutations
in the Japanese population.
Previous studies showed thatHLA-B*51:01-restricted, Pol283-
8-specificCTLs have a strong ability to suppressHIV-1 replication
in vitro (28) and that they suppressed the replication of the 8V
mutant virus but failed to suppress that of the 8T, 8L, and 8R
mutant viruses (15). The frequency of the Pol283-8-specific CTLs
was inversely correlated with the plasma viral load in HLA-B*51:
01 hemophiliacs infected with HIV-1 approximately 30 years
ago (28). The 8T, 8L, and 8R mutations did not affect replication
capacity, whereas the 8Vmutation conferred amodest fitness cost
(15). These findings support the suppression of the wild-type or
8Vmutant virus by Pol283-8-specific CTLs as amajormechanism
of slow progression to AIDS in Japanese hemophiliacs. This CTL
response was also elicited in Chinese HLA-B*51:01 individuals
infected with the 8V mutant virus; furthermore, a low viral load
and a high CD4 count were significantly associated with the pres-
ence of at least one of three HLA-B*51:01-restricted CTL re-
sponses, including a Pol283-8-specific one (50). Thus, these find-
ings support the idea that Pol283-8-specific CTLs play an
important role in the control of HIV-1 infection.
The present study demonstrated that HLA-B*52:01-restricted,
Pol283-8-specificCTLs also had a strong ability to suppressHIV-1
replication in vitro (80% suppression at an E/T cell ratio of 0.3:1).
However, the ability of HLA-B*52:01-restricted CTLs to suppress
the replication of HIV-1 was weaker than that of HLA-B*51:01-
restricted CTLs (Fig. 5B). Inspection of the crystal structures of
both HLA molecules complexed with the Pol283-8 peptide sug-
gests that the relatively shallow penetration of the hydrophobic
groove of HLA-B*52:01 by the C-terminal side of the peptide, in
contrast to the tightly packed binding with HLA-B*51:01, may
have resulted in an unstable conformation of the complex. Fur-
thermore, Ser67 of HLA-B*52:01 would have provided more
space and loose interactions with the peptide than in the case of
the Phe of HLA-B*51:01. Interestingly, the Pol283-8 peptide
would have displayed only side chains of Thr1 and Ser7, and some
part of the main chains, to CTLs. Therefore, these results suggest
that the unstable backbone conformation and side chain positions
in the case of HLA-B*52:01 largely contributed to the lower TCR
affinity than that afforded by HLA-B*51:01. These results support
that selection pressure in vivo via the HLA-B*52:01-restricted
CTLs would be weaker than that via the HLA-B*51:01-restricted
CTLs. Indeed, the prevalence of I135X mutations in HLA-B*51:
TABLE 3 Numbers and frequencies of individuals having I135X mutations in a Japanese cohort and a predominantly Caucasian cohort
Cohort
No./total no. (%) of individuals
B*51:01 B*52:01 B*51:01 B*52:01 B*51:01 B*52:01 B*51:01 B*52:01 Total
Japanese 51/51 (100) 42/49 (85.7) 5/5 (100) 88/151 (58.3) 186/256 (72.6)
Caucasian 125/131 (95.4) 17/26 (65.4) 0/0 331/1,198 (27.6) 473/1,355 (34.9)
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01 individuals was higher than that in HLA-B*52:01 individu-
als. The difference in the pattern of escape mutant selection by
these CTLs between the HLA-B*51:01 and HLA-B*52:01 indi-
viduals might also have been due to the difference in their abilities
to suppress HIV-1 replication. However, it still remains unclear
why the 8Tmutant was predominantly selected in the HLA-B*51:
01 but not in the HLA-B*52:01 individuals. Further studies are
expected to clarify the mechanism to explain how these CTLs se-
lected different patterns of mutations at RT135.
Previous studies showed that the T242N mutant was selected
by HLA-B*58:01-restricted and HLA-B*57-restricted CTLs spe-
cific for TW10 epitope in HIV-1 clade B-infected and clade C-in-
fected individuals (25–27). Herein we also showed that I135X was
selected by Pol283-8-specific CTLs restricted by two different
HLA class I molecules. However, the strength and the pattern of
the selection of I135X was different between HLA-B*51:01 and
HLA-B*52:01. The present study suggests that this difference in
the selection pattern was associated with that between the HLA-
B*51:01 andHLA-B*52:01 individuals in terms of the ability of
Pol283-specific CTLs to suppress HIV-1 replication. Thus, we
characterized and experimentally validated distinct HIV-1 escape
patterns of CTLs with the same epitope specificity and provided
evidence that the extremely high prevalence of 135X in circulating
Japanese sequences is likely driven not by one but by two HLA-B
alleles.
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